KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Future oncology (London, England), vol.15, pp.1057-1066, 2019 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 15
- Publication Date: 2019
- Doi Number: 10.2217/fon-2018-0609
- Journal Name: Future oncology (London, England)
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.1057-1066
- Keywords: chemotherapy, esophageal cancer, esophagogastric junction cancer, gastrointestinal/esophageal, immunotherapy, PD-1, PD-L1, pembrolizumab, squamous cell carcinoma of the esophagus, SQUAMOUS-CELL CARCINOMA, GASTROESOPHAGEAL JUNCTION, SUPPORTIVE CARE, GASTRIC-CANCER, OPEN-LABEL, ADENOCARCINOMA, PLUS, PACLITAXEL, IRINOTECAN, BLOCKADE
- Open Archive Collection: AVESIS Open Access Collection
- Istanbul University-Cerrahpasa Affiliated: No